{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T14:35:53Z","timestamp":1781706953469,"version":"3.54.5"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.yebeh.2020.106939","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T18:47:30Z","timestamp":1581360450000},"page":"106939","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"special_numbering":"PA","title":["Pharmacodynamic interactions of antiepileptic drugs: From bench to clinical practice"],"prefix":"10.1016","volume":"104","author":[{"given":"Alberto","family":"Verrotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Lattanzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Brigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Zaccara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2020.106939_bb0005","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1212\/01.wnl.0000252807.38124.a3","article-title":"How common are the \u201ccommon\u201d neurologic disorders?","volume":"68","author":"Hirtz","year":"2007","journal-title":"Neurology."},{"key":"10.1016\/j.yebeh.2020.106939_bb0010","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1212\/WNL.0000000000003509","article-title":"Prevalence and incidence of epilepsy a systematic review and meta-analysis of international studies","volume":"88","author":"Fiest","year":"2017","journal-title":"Neurology."},{"key":"10.1016\/j.yebeh.2020.106939_bb0015","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.eplepsyres.2017.11.001","article-title":"Utilisation and polypharmacy aspects of antiepileptic drugs in elderly versus younger patients with epilepsy: a pharmacoepidemiological study of CNS-active drugs in Norway","volume":"139","author":"Baftiu","year":"2004","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2020.106939_bb0020","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl Med"},{"key":"10.1016\/j.yebeh.2020.106939_bb0025","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1468-1331.2006.01215.x","article-title":"Diagnosing refractory epilepsy: response to sequential treatment schedules","volume":"13","author":"Mohanraj","year":"2006","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.yebeh.2020.106939_bb0030","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1212\/WNL.0b013e3182563b19","article-title":"Patterns of treatment response in newly diagnosed epilepsy","volume":"78","author":"Brodie","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2020.106939_bb0035","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.eplepsyres.2017.07.011","article-title":"Outcome of treatment changes in patients with drug-resistant chronic epilepsy: a tertiary center experience","volume":"136","author":"Mart\u00ednez-Lizana","year":"2017","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2020.106939_bb0040","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.yebeh.2020.106939_bb0045","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/seiz.2000.0442","article-title":"Epilepsy after the first drug fails: substitution or add-on?","volume":"9","author":"Kwan","year":"2000","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2020.106939_bb0050","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00415-005-0735-x","article-title":"Medical therapy of epilepsy: when to initiate treatment and when to combine?","volume":"252","author":"Brodie","year":"2005","journal-title":"J Neurol"},{"key":"10.1016\/j.yebeh.2020.106939_bb0055","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.eplepsyres.2018.03.011","article-title":"Comparative efficacy of unique antiepileptic drug regimens in focal epilepsy: an exploratory study","volume":"142","author":"Legge","year":"2018","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2020.106939_bb0060","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.eplepsyres.2017.10.004","article-title":"Efficacy of antiepileptic drugs in the adjunctive treatment of refractory partial-onset seizures: meta-analysis of pivotal trials","volume":"143","author":"Slater","year":"2018","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2020.106939_bb0065","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrneurol.2016.135","article-title":"Epilepsy: beyond seizures-the importance of comorbidities in epilepsy","volume":"12","author":"Verrotti","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.yebeh.2020.106939_bb0070","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/S0022-3565(25)13268-0","article-title":"Combination of valproate and ethosuximide: antiepileptic and neurotoxic interaction","volume":"247","author":"Bourgeois","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.yebeh.2020.106939_bb0075","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/00002826-198808000-00003","article-title":"Anticonvulsant potency and neurotoxicity of valproate alone and in combination with carbamazepine or phenobarbital","volume":"11","author":"Bourgeois","year":"1988","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.yebeh.2020.106939_bb0080","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1528-1157.1988.tb03749.x","article-title":"Combined administration of carbamazepine and phenobarbital: effect on anticonvulsant activity and neurotoxicity","volume":"29","author":"Bourgeois","year":"1988","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.106939_bb0085","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/BF00500017","article-title":"Antiepileptic drug combinations and experimental background: the case of phenobarbital and phenytoin","volume":"333","author":"Bourgeois","year":"1986","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.yebeh.2020.106939_bb0090","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1684\/epd.2014.0714","article-title":"Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs","volume":"16","author":"Zaccara","year":"2014","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2020.106939_bb0095","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1185\/030079907X210499","article-title":"Zonisamide and renal calculi in patients with epilepsy: how big an issue?","volume":"23","author":"Wroe","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.yebeh.2020.106939_bb0100","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.seizure.2011.01.004","article-title":"Combining antiepileptic drugs - rational polytherapy?","volume":"20","author":"Brodie","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2020.106939_bb0105","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1528-1167.2007.01402.x","article-title":"Weight issues for people with epilepsy - a review","volume":"48","author":"Ben-Menachem","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.106939_bb0110","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s11065-007-9043-9","article-title":"Neuropsychological and behavioral effects of antiepilepsy drugs","volume":"17","author":"Loring","year":"2007","journal-title":"Neuropsychol Rev"},{"key":"10.1016\/j.yebeh.2020.106939_bb0115","doi-asserted-by":"crossref","first-page":"5639","DOI":"10.2174\/1381612823666170926103631","article-title":"Specific patient features affect antiepileptic drug therapy decisions: focus on gender, age and psychiatric comorbidities","volume":"23","author":"Pisani","year":"2017","journal-title":"Curr Pharm Res"},{"key":"10.1016\/j.yebeh.2020.106939_bb0120","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/00002826-199402000-00003","article-title":"Pharmacodynamic interactions between phenytoin and valproate: individual and combined antiepileptic and neurotoxic actions in mice","volume":"17","author":"Chez","year":"1994","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.yebeh.2020.106939_bb0125","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1046\/j.1528-1157.2003.10003.x","article-title":"Interactions of lamotrigine with topiramate and first-generation antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis","volume":"44","author":"Luszczki","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.106939_bb0130","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1038\/sj.npp.1300243","article-title":"Tiagabine synergistically interacts with gabapentin in the electroconvulsive threshold test in mice","volume":"28","author":"Luszczki","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.yebeh.2020.106939_bb0135","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.euroneuro.2006.06.008","article-title":"Interactions between zonisamide and conventional antiepileptic drugs in the mouse maximal electroshock test model","volume":"17","author":"Borowicz","year":"2007","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.yebeh.2020.106939_bb0140","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1046\/j.1528-1157.2003.32702.x","article-title":"Interactions between oxcarbazepine and conventional antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis","volume":"44","author":"Luszczki","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.106939_bb0145","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1046\/j.1528-1157.2002.34301.x","article-title":"Effect of gabapentin on the anticonvulsant activity of antiepileptic drugs against electroconvulsions in mice: an isobolographic analysis","volume":"43","author":"Borowicz","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.106939_bb0150","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1111\/j.1528-1167.2006.00825.x","article-title":"Characterization of the anticonvulsant, behavioral and pharmacokinetic interaction profiles of stiripentol in combination with clonazepam, ethosuximide, phenobarbital, and valproate using isobolographic analysis","volume":"47","author":"Luszczki","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.106939_bb0155","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1528-1157.1994.tb02459.x","article-title":"Topiramate: preclinical evaluation of structurally novel anticonvulsant","volume":"35","author":"Shank","year":"1994","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.106939_bb0160","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejphar.2008.12.046","article-title":"Pharmacodynamic and pharmacokinetic interaction profiles of levetiracetam in combination with gabapentin, tiagabine and vigabatrin in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis","volume":"605","author":"Dudra-Jastrzebska","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.yebeh.2020.106939_bb0165","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ejphar.2013.10.063","article-title":"Interactions of levetiracetam with carbamazepine, phenytoin, topiramate and vigabatrin in the mouse 6 Hz psychomotor seizure model - a type II isobolographic analysis","volume":"723","author":"Florek-Luszczki","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.yebeh.2020.106939_bb0170","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2478\/v10039-010-0005-8","article-title":"Interaction of pregabalin with carbamazepine in the mouse maximal electroshock-induced seizure model: a type I isobolographic analysis for non-parallel dose-response relationship curves","volume":"55","author":"Luszczki","year":"2010","journal-title":"Adv Med Sci"},{"key":"10.1016\/j.yebeh.2020.106939_bb0175","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2478\/v10039-009-0006-7","article-title":"Interaction of tiagabine with valproate in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis for non-parallel dose-response relationship curves","volume":"54","author":"Luszczki","year":"2009","journal-title":"Adv Med Sci"},{"key":"10.1016\/j.yebeh.2020.106939_bb0180","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.0013-9580.2004.05104.x","article-title":"Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis","volume":"45","author":"Luszczki","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.106939_bb0185","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00210-007-0144-z","article-title":"Isobolographic analysis of interaction between drugs with nonparallel dose-response relationship curves: a practical application","volume":"375","author":"Luszczki","year":"2007","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.yebeh.2020.106939_bb0190","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejphar.2005.03.046","article-title":"Synergistic interaction of gabapentin and oxcarbazepine in the mouse maximal electroshock seizure model - an isobolographic analysis","volume":"515","author":"Luszczki","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.yebeh.2020.106939_bb0195","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejphar.2008.07.051","article-title":"Isobolographic and behavioral characterizations of interactions between vigabatrin and gabapentin in two experimental models of epilepsy","volume":"595","author":"Luszczki","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.yebeh.2020.106939_bb0200","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00210-004-0867-z","article-title":"Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study","volume":"369","author":"Luszczki","year":"2004","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.yebeh.2020.106939_bb0205","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00210-005-1088-9","article-title":"Isobolographiccharacterisation of interactions among selected newer antiepileptic drugs in the mouse pentylenetetrazole-induced seizure model","volume":"372","author":"Luszczki","year":"2005","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.yebeh.2020.106939_bb0210","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.eplepsyres.2010.07.009","article-title":"Additive interactions of pregabalin with lamotrigine, oxcarbazepine and topiramate in the mouse maximal electroshock-induced seizure model: a type I isobolographic analysis for non-parallel dose-response relationship curves","volume":"91","author":"Luszczki","year":"2010","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2020.106939_bb0215","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000430822","article-title":"Synergistic interaction of retigabine with levetiracetam in the mouse maximal electroshock-induced seizure model: a type II isobolographic analysis","volume":"96","author":"Luszczki","year":"2015","journal-title":"Pharmacology"},{"key":"10.1016\/j.yebeh.2020.106939_bb0220","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.eplepsyres.2009.06.003","article-title":"Isobolographic characterization of interactions of levetiracetam with the various antiepileptic drugs in the mouse 6 Hz psychomotor seizure model","volume":"86","author":"Wojda","year":"2009","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2020.106939_bb0225","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/epi.12237","article-title":"Synergism of lacosamide with established antiepileptic drugs in the 6-Hz seizure model in mice","volume":"54","author":"Shandra","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.106939_bb0230","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/epi.13328","article-title":"Synergism of perampanel and zonisamide in the rat amygdala kindling model of temporal lobe epilepsy","volume":"57","author":"Russmann","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.106939_bb0235","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0920-1211(02)00073-6","article-title":"Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy","volume":"50","author":"L\u00f6scher","year":"2002","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2020.106939_bb0240","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000480019","article-title":"Beneficial combination of lacosamide with retigabine in experimental animals: an isobolographic analysis","volume":"101","author":"Luszczki","year":"2018","journal-title":"Pharmacology"},{"key":"10.1016\/j.yebeh.2020.106939_bb0245","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000444452","article-title":"Isobolographic analysis of interaction for three-drug combination of carbamazepine, phenobarbital and topiramate in the mouse maximal electroshock-induced seizure model","volume":"97","author":"Luszczki","year":"2016","journal-title":"Pharmacology"},{"key":"10.1016\/j.yebeh.2020.106939_bb0250","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/j.1528-1157.2000.tb00111.x","article-title":"Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed","volume":"41","author":"Deckers","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.106939_bb0255","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/17512433.2018.1500895","article-title":"A viewpoint on rational and irrational fixed-drug combinations","volume":"11","author":"B\u0142aszczyk","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2020.106939_bb0260","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0140-6736(93)93048-6","article-title":"Interaction of lamotrigine with sodium valproate","volume":"341","author":"Panayiotopoulos","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2020.106939_bb0265","first-page":"71","article-title":"Efficacia dell'associazione lamotrigina-valproato di sodio nelle crisi epilettiche parziali resistenti","volume":"58","author":"Pisani","year":"1992","journal-title":"Q Acta Neurol"},{"key":"10.1016\/j.yebeh.2020.106939_bb0270","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1059-1311(05)80208-0","article-title":"Therapeutic interaction of lamotrigine and sodium valproate in intractable myoclonic epilepsy","volume":"3","author":"Ferrie","year":"1994","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2020.106939_bb0275","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(94)90741-2","article-title":"Lamotrigine in infantile spasms","volume":"344","author":"Veggiotti","year":"1994","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.yebeh.2020.106939_bb0280","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1600-0404.1995.tb00434.x","article-title":"Lamotrigine as an add-on drug in typical absence seizures","volume":"91","author":"Ferrie","year":"1995","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2020.106939_bb0285","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0920-1211(96)01007-8","article-title":"Lamotrigine substitution study: evidence for synergism with sodium valproate?","volume":"26","author":"Brodie","year":"1997","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2020.106939_bb0290","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/j.1528-1157.1999.tb00832.x","article-title":"The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction","volume":"40","author":"Pisani","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.106939_bb0295","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1001\/archneur.58.8.1264","article-title":"Effect of divalproex-lamotrigine combination therapy in frontal lobe seizures","volume":"58","author":"McCabe","year":"2001","journal-title":"Arch Neurol"},{"key":"10.1016\/j.yebeh.2020.106939_bb0300","series-title":"The treatment of epilepsy","first-page":"498","article-title":"Lamotrigine","author":"Riaz","year":"2016"},{"key":"10.1016\/j.yebeh.2020.106939_bb0305","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0140-6736(93)91398-6","article-title":"Disabling tremor after lamotrigine with sodium valproate","volume":"342","author":"Reutens","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2020.106939_bb0310","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1528-1157.1999.tb00831.x","article-title":"Adding lamotrigine to valproate: incidence of rash and other adverse effects","volume":"40","author":"Faught","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.106939_bb0315","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/archneur.1983.04050120047006","article-title":"Valproate-ethosuximide combination therapy for refractory absence seizures","volume":"40","author":"Rowan","year":"1983","journal-title":"Arch Neurol"},{"key":"10.1016\/j.yebeh.2020.106939_bb0320","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ejpn.2015.07.008","article-title":"Refractory absence seizures: an italian retrospective multicenter study","volume":"19","author":"Franzoni","year":"2015","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.yebeh.2020.106939_bb0325","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.eplepsyres.2004.04.003","article-title":"Effects of the combination of valproate and ethosuximide on spike-waves discharges in WAG\/Ri","volume":"59","author":"van Rijn","year":"2004","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2020.106939_bb0330","article-title":"Antiepileptic drugs for the treatment of infants with severe myoclonic epilepsy","volume":"5","author":"Brigo","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.yebeh.2020.106939_bb0335","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.yebeh.2013.03.010","article-title":"When one plus one makes three: the quest for rational antiepileptic polytherapy with supraadditive anticonvulsant efficacy","volume":"27","author":"Brigo","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.106939_bb0340","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/14728214.2018.1552937","article-title":"Emerging drugs for the treatment of Dravet syndrome","volume":"23","author":"Brigo","year":"2018","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.yebeh.2020.106939_bb0345","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s40265-018-0992-5","article-title":"Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta-analysis","volume":"78","author":"Lattanzi","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.yebeh.2020.106939_bb0350","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.lfs.2011.05.018","article-title":"Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes","volume":"89","author":"Jiang","year":"2011","journal-title":"Life Sci"},{"key":"10.1016\/j.yebeh.2020.106939_bb0355","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1124\/dmd.111.041384","article-title":"Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6","volume":"39","author":"Yamaori","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.yebeh.2020.106939_bb0360","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/epi.13060","article-title":"Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy","volume":"56","author":"Geffrey","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.106939_bb0365","doi-asserted-by":"crossref","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","article-title":"Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome","volume":"90","author":"Devinsky","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2020.106939_bb0370","author":"Food and Drug Administration US"},{"key":"10.1016\/j.yebeh.2020.106939_bb0375","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/cpt1975186733","article-title":"The efficacy of carbamazepine combinations in epilepsy","volume":"18","author":"Cereghino","year":"1975","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.yebeh.2020.106939_bb0380","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(05)60613-7","article-title":"Lamotrigine and topiramate may be a useful combination","volume":"351","author":"Stephen","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2020.106939_bb0385","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(03)00409-5","article-title":"Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs","volume":"2","author":"Patsalos","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2020.106939_bb0390","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2165\/00003495-200666140-00004","article-title":"Combination therapy in epilepsy: when and what to use","volume":"66","author":"Kwan","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.yebeh.2020.106939_bb0395","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40261-017-0585-1","article-title":"The challenge of pharmacotherapy in children and adolescents with epilepsy-ADHD comorbidity","volume":"38","author":"Verrotti","year":"2018","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.yebeh.2020.106939_bb0400","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1528-1157.1998.tb01356.x","article-title":"Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?","volume":"39","author":"Besag","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.106939_bb0405","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/11587550-000000000-00000","article-title":"A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs","volume":"24","author":"Sake","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2020.106939_bb0410","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.2165\/11594640-000000000-00000","article-title":"Novel medications for epilepsy","volume":"71","author":"Fattore","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.yebeh.2020.106939_bb0415","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2165\/11587900-000000000-00000","article-title":"The pharmacology of new antiepileptic drugs: does a novel mechanism of action really matter?","volume":"25","author":"Perucca","year":"2011","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.yebeh.2020.106939_bb0420","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.yebeh.2011.11.026","article-title":"Rational polytherapy with lacosamide in clinical practice: results of a Spanish cohort analysis RELACOVA","volume":"23","author":"Villanueva","year":"2012","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.106939_bb0425","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.clineuro.2018.06.022","article-title":"Lacosamide efficacy and tolerability in clinical practice - post marketing analysis from a single dedicated epilepsy center","volume":"171","author":"Baker","year":"2018","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.yebeh.2020.106939_bb0430","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1517\/14656566.2012.713347","article-title":"Lacosamide in patients with pharmacoresistant epilepsy","volume":"13","author":"Verrotti","year":"2012","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.yebeh.2020.106939_bb0435","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0074-7742(06)81006-8","article-title":"Mechanisms of action of antiepileptic drugs","volume":"81","author":"White","year":"2007","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.yebeh.2020.106939_bb0440","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/ane.13025","article-title":"Antiepileptic monotherapy in newly diagnosed focal epilepsy. A network meta-analysis","volume":"139","author":"Lattanzi","year":"2019","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2020.106939_bb0445","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1002\/jcb.25936","article-title":"Evaluate the efficacy and safety of anti-epileptic medications for partial seizures of epilepsy: a network meta-analysis","volume":"118","author":"Zhao","year":"2017","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.yebeh.2020.106939_bb0450","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0140-6736(98)10531-7","article-title":"Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group","volume":"354","author":"Chadwick","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2020.106939_bb0455","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1474-4422(11)70154-5","article-title":"Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial","volume":"10","author":"Kwan","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2020.106939_bb0460","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1684\/epd.2019.1083","article-title":"Antiepileptic drugs: evolution of our knowledge and changes in drug trials","volume":"21","author":"Perucca","year":"2019","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2020.106939_bb0465","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1528-1167.2009.02238.x","article-title":"Rational polytherapy","volume":"50","author":"French","year":"2009","journal-title":"Epilepsia"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505019310728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505019310728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:31:49Z","timestamp":1761503509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505019310728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":93,"alternative-id":["S1525505019310728"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2020.106939","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacodynamic interactions of antiepileptic drugs: From bench to clinical practice","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2020.106939","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106939"}}